Alembic Pharma gets US FDA approval for paliperidone ER tablets: Our Bureau, Bengaluru Monday, September 30, 2024, 11:30 Hrs [IST] Alembic Pharmaceuticals has received final appro ...
The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.